Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Axonics, Inc.
  6. Summary
    AXNX   US05465P1012

AXONICS, INC.

(AXNX)
  Report
Delayed Nasdaq  -  04:00 2022-09-30 pm EDT
70.44 USD   -0.47%
09/21Insider Sell: Axonics
MT
09/12Transcript : Axonics, Inc. Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-12-2022 11:05 AM
CI
09/08Axonics Reports First Patient Implants in Canada
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/26/2022 09/27/2022 09/28/2022 09/29/2022 09/30/2022 Date
67.34(c) 68.51(c) 70.97(c) 70.77(c) 70.44(c) Last
523 135 349 723 477 948 397 064 541 527 Volume
+3.22% +1.74% +3.59% -0.28% -0.47% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 253 M - -
Net income 2022 -83,2 M - -
Net cash position 2022 117 M - -
P/E ratio 2022 -38,4x
Yield 2022 -
Sales 2023 317 M - -
Net income 2023 -62,3 M - -
Net cash position 2023 135 M - -
P/E ratio 2023 -53,6x
Yield 2023 -
Capitalization 3 460 M 3 460 M -
EV / Sales 2022 13,2x
EV / Sales 2023 10,5x
Nbr of Employees 517
Free-Float 91,8%
More Financials
Company
Axonics, Inc. is a medical technology company. It is engaged in developing and commercializing products for patients with bladder and bowel dysfunction. The bladder and bowel dysfunction includes implantable sacral neuromodulation (SNM) systems to treat urinary urge incontinence (UUI) and urinary urgency frequency (UUF), together referred to as overactive bladder (OAB), as well as fecal incontinence (FI), and... 
More about the company
Ratings of Axonics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about AXONICS, INC.
09/21Insider Sell: Axonics
MT
09/12Transcript : Axonics, Inc. Presents at Morgan Stanley 20th Annual Global Heal..
CI
09/08Axonics Reports First Patient Implants in Canada
MT
09/08Axonics® Announces First Patient Implants in Canada With New Recharge-Free Sacral Neuro..
BU
09/08Axonics Announces First Patient Implants in Canada with New Recharge-Free Sacral Neurom..
CI
09/02Certain Restricted Stock Units of Axonics, Inc. are subject to a Lock-Up Agreement Endi..
CI
09/02Certain Stock Options of Axonics, Inc. are subject to a Lock-Up Agreement Ending on 2-S..
CI
09/02Certain Common Stock of Axonics, Inc. are subject to a Lock-Up Agreement Ending on 2-SE..
CI
08/18Axonics® to Participate in September Investor Conferences
BU
08/17Axonics® Expands Sacral Neuromodulation Intellectual Property Portfolio
BU
08/15Insider Sell: Axonics
MT
08/11Insider Sell: Axonics
MT
08/08Axonics Announces Closing of Public Stock Offering and Full Exercise of Underwriter's O..
AQ
08/05Axonics : reg; Announces Proposed Public Offering of Common Stock - Form 8-K
PU
08/05Axonics, Inc. : Entry into a Material Definitive Agreement, Other Events, Financial Statem..
AQ
More news
News in other languages on AXONICS, INC.
09/08Axonics annonce l'implantation des premiers patients au Canada avec le nouveau système ..
08/15Vente d'initiés : Axonics
08/11Vente d'initiés : Axonics
08/03Axonics lance une offre d'actions ordinaires
08/01Axonics réduit sa perte nette au 2e trimestre, augmente ses revenus et revoit à la haus..
More news
Analyst Recommendations on AXONICS, INC.
More recommendations
ETFs positioned on AXONICS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
INNOVATOR IBD 50 ETF - Distributing - USD1.99%1.58%United_States
First Trust Small Cap Growth AlphaDEX Fund - USD0.53%0.06%NC
First Trust US Equity Opportunities ETF - USD0.35%-2.05%United_States
First Trust US Equity Opportunities - USD0.34%2.03%United_States
IShares U.S. Medical Devices ETF - USD0.28%-1.85%United_States
More ETFs positioned on AXONICS, INC.
Chart AXONICS, INC.
Duration : Period :
Axonics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AXONICS, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 70,44 $
Average target price 81,71 $
Spread / Average Target 16,0%
EPS Revisions
Managers and Directors
Raymond Wayne Cohen Chief Executive Officer & Director
Danny L. Dearen President & Chief Financial Officer
Michael H. Carrel Chairman
Guang Qiang Jiang Chief Technology Officer
Karen Noblett Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
AXONICS, INC.25.79%3 460
STRYKER CORPORATION-24.26%76 625
SMITH & NEPHEW PLC-18.79%10 178
INSPIRE MEDICAL SYSTEMS, INC.-22.90%5 106
GLAUKOS CORPORATION19.80%2 533
DOUBLE MEDICAL TECHNOLOGY INC.-20.60%2 334